RLYB earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Hold, P/E -11.15. Updated 2026-07-23.
Rallybio (RLYB) Research Hub
Rallybio (RLYB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 16.875 USD (-0.56%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -11.15, market cap 0.09B. This hub links to the full technical, earnings and options research available for RLYB.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 16.875 USD (-0.56%) |
| 52-week range | 15.61 USD – 17.35 USD |
| Trend regime | Range |
| 14-day RSI | 65.6 (Bullish) |
| Trailing P/E | -11.15 |
| Market cap | 0.09B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for RLYB
Covered Call on RLYB: how it works, illustrative setup around the real 16.88 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RLYB: how it works, illustrative setup around the real 16.88 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RLYB: how it works, illustrative setup around the real 16.88 USD price, max profit/loss, breakeven and when to use it. Educational.
RLYB technical analysis: range, last 16.875 USD, RSI 65.6, 52w range 15.61 USD–17.35 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is RLYB in?
Rallybio (RLYB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is RLYB in an uptrend or downtrend?
As of 2026-09-11, RLYB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RLYB's trailing P/E ratio?
RLYB's trailing P/E is -11.15, with a market cap of 0.09B. See the earnings research page for full valuation detail.
When does RLYB next report earnings?
RLYB is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -1.28 USD.